ProPharma   Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (2016)
Status: No NME R&D (2016)

Organization Overview

First Clinical Trial
2021
NCT04846036
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

gkitson@propharmapartners.uk.com | ProPharma Group | ProPharma Partners Limited

Active Ingredients

Drugs in Phase 2 Trials (3)

Key: ProPharma (2) Acquired (1)

bovine intestinal alkaline phosphatase (1 trial)

gbs-nn/nn2 (3 trials)

kh176 (2 trials)

Drugs in Phase 1 Trials (1)

mCBM40 (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4